2014 Life Sciences Outlook in Turkey

Rapid Economic Development and Healthcare Reforms Set the Stage for the Future

Regular Price: USD 2,450

Special Price USD 2,205

10% OFF

* Required Fields

Regular Price: USD 2,450

Special Price USD 2,205

PAY BY INVOICE

Be the first to review this product

The Turkish pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe, valued at $14.04 billion in 2013 and projected to grow at a CAGR of 9.1% from 2013 to 2018. Growth is driven by expanding public insurance, modernisation, prevalence of chronic diseases, increasing health awareness, and affluence. Market segmentation is based on products (e.g., over-the-counter, generic, and patented drugs) and therapeutic areas (e.g., antibiotics, anti-rheumatics, cardiovascular, analgesics, oncology, cough preparations, and central nervous system). The study provides a macroeconomic overview of Turkey’s mergers and acquisitions/investment trends, regulatory environment, revenue forecasts, key trends, and companies to watch.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Study Scope and Market OverviewStudy ScopeStudy Scope—Segmentation of the Pharmaceutical IndustryStudy Scope—Segmentation of Pharmaceutical Industry (continued)Study Scope—Segmentation of Pharmaceutical Industry (continued)Total Life Sciences Market—SegmentationTurkey Life Sciences Market—Snapshot State of Turkey Life Sciences in 2012 and 2013Top 3 Growth SectorsAccelerating Trends Make Their Mark in TurkeyMNCs to Watch—High Tech, M&A, and Value-based Products to Capitalize on First-mover AdvantageDomestic Companies to Watch—Pioneers of R&D Paving the Way for Innovation in TurkeyMedical Tourism Market—Still AttractiveStrategic Action Plan for the Pharmaceuticals Segment– Current Ranking and Vision 2023Macroeconomic Overview of the Turkish Pharmaceutical IndustryTurkey—A Rapid-growing Economy History of the Turkish Pharmaceutical IndustryHTP—OverviewHTP—Major Reforms 2003 to 2010HTP—Strategic Plan 2010 to 2014Impact of the HTP—Universal Health InsuranceImpact of the HTP—FP ServicesImpact of the HTP—Management of Diseases and Promotion of HealthHTP—Regional Development of InfrastructureImpact of the HTP—Development of Health InfrastructureImpact of the HTP—Increased Healthcare SpendingImpact of the HTP—Increased Healthcare Spending (continued)Impact of the HTP—Increased Pharmaceutical SpendingImpact of the HTP—Tapering Out-of-pocket PaymentDemographics and Disease BurdenDemographics—Aging PopulationDemographics—Young Workforce and Employment Demographics—Key Health Indicators and Top Causes of DeathDisease Burden—Prevalence Rates of Top DiseasesDisease Burden—Incidences of Top Infectious DiseasesDisease Burden—Cancer Incidence RatesAnalysis of the Turkish Pharmaceuticals SegmentPharmaceuticals Segment Analysis Pharmaceuticals Segment—Revenue ForecastPharmaceuticals Segment—Percent Revenue Forecast by ProductPharmaceuticals Segment—Percent Revenue Forecast by Therapeutic AreaGrowth Opportunities in the Pharmaceuticals SegmentChallenges in the Pharmaceuticals SegmentPharmaceuticals Segment—SWOT AnalysisMergers and Acquisitions and Investment Trends—Are You Putting Your Money in the Right Market?Turkey—A Lucrative Hub for Foreign InvestorsBig Pharma Heavy Investment Plans in TurkeyM&A Activity Intensifies in TurkeyM&A Activity Intensifies in Turkey (continued)Government Initiatives to Foster Research and Development and InnovationTurkey Clinical Research Attractiveness IndexIncentive Programs to Foster R&D and Innovation in TurkeyR&D Incentive Programs—TUBITAK-TEYDEBR&D Incentive Programs—TDZR&D Incentive Programs—SAN-TEZSAN-TEZKey Research Centres Active in Pharmaceutical R&DKey International Companies Active in Pharmaceutical R&DKey International Companies Active in Pharmaceutical R&D (continued)Key Local Companies Active in Pharmaceutical R&DPharmaceuticals Segment Value Chain—Key Stakeholders Influencing Production and SalesPharmaceutical Production—Export-Import RatioPharmaceutical Raw Materials Production—Key StakeholdersPharmaceutical Raw Materials Production—Key Stakeholders (continued)Pharmaceutical Raw Materials Production—Key Stakeholders (continued)Pharmaceutical Production Capacity UtilisationTop 10 Pharmaceutical Companies in Turkey Pharmaceutical Production—Key StakeholdersPharmaceutical Wholesale Market—TurkeyPharmaceutical Wholesale Market—Key StakeholdersPharmaceutical Retail Market—TurkeyRegulatory Environment—An Integral Part of Any Healthcare ConversationKey Regulatory Bodies that Govern the Turkish Pharmaceutical IndustryKey Regulatory Bodies that Govern the Turkish Pharmaceutical Industry (continued)Key Regulatory Bodies that Govern the Turkish Pharmaceutical Industry (continued)Turkey’s SSI (SGK) Healthcare CoveragePharmaceutical Pricing Regulation in Turkey Pharmaceutical Reimbursement Regulation in TurkeyPharmaceuticals Segment—Reimbursements in TurkeyPharmaceutical Licensing Procedure in TurkeyPharmaceutical Licensing RegulationAnalysis of the Turkish Clinical Diagnostics SegmentClinical Diagnostics Segment Analysis Clinical Diagnostics Segment—Revenue ForecastClinical Diagnostics Segment—Revenue Forecast by Sub-segmentGrowth Opportunities in the Clinical Diagnostics SegmentChallenges in the Clinical Diagnostics SegmentTurkey to Emerge as the Regional (MENA) Life Sciences Capital—Government’s Vision 2023Turkey—A Developing Regional Life Sciences CapitalFree Healthcare Zones—A Strategic Initiative Propelled by the Growing Medical Tourism Industry in TurkeyMoH—Strategic Plan 2013 to 2017: Improvement of Public HealthMinistry of Science, Industry, and Technology—Strategic GoalsThe Government’s 2023 VisionThe Last Word—3 Big PredictionsLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue PropositionGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Release Date : 20-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 18-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.